Please login to the form below

Not currently logged in


This page shows the latest Flutiform news and features for those working in and with pharma, biotech and healthcare.

Vectura's Flutiform flunks phase III COPD test

Vectura's Flutiform flunks phase III COPD test

Vectura's hopes of extending the uses of its asthma drug Flutiform into chronic obstructive pulmonary disease (COPD) have been dashed by disappointing phase III data. ... Flutiform sales doubled last year to reach 144m in 2015, and in the first six

Latest news

  • Vectura to merge with SkyePharma in £441m deal Vectura to merge with SkyePharma in £441m deal

    SkyePharma has just reported record revenues for 2015 of £95m, up 30% with the help of rising royalties and product supply fees for asthma therapy Flutiform (fluticasone/formoterol) and GlaxoSmithKline's

  • Successful partnerships in pharma: Skyepharma and Mundipharma Successful partnerships in pharma: Skyepharma and Mundipharma

    Why skills and flexibility matter more than sheer size. Skyepharma and Mundipharma collaborated on the respiratory drug Flutiform. ... was able to make decisions quickly and was equally committed to the success of Flutiform.

  • Double asthma approval in Japan lifts SkyePharma Double asthma approval in Japan lifts SkyePharma

    The Japanese Ministry of Health, Labour and Welfare (MHLW) cleared GlaxoSmithKline's (GSK) Relvar Ellipta (vilanterol and fluticasone), as well as Kyorin Pharmaceutical's Flutiform (formoterol and fluticasone) for the treatment ... Meanwhile, the

  • Portland Health wins Mundipharma account

    High on the Portland Health's agenda will be to raise the profile of the recently launched asthma drug Flutiform (fluticasone/formoterol).

  • Pharma news in brief

    Our weekly round-up of news affecting the industry. SkyePharma signs key Flutiform marketing deal. ... SkyePharma has finally signed a US marketing agreement for its key asthma treatment, Flutiform, with Kos Pharmaceuticals, a deal which could be worth

More from news
Approximately 2 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Interview: Georg Toufar, Mundipharma Interview: Georg Toufar, Mundipharma

    Treatments successfully brought to market in this way include asthma treatment Flutiform, created by Skye Pharma, and restless legs syndrome treatment Targin.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...